Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure (IF) due to microvillus inclusion disease (MVID) in an infant in the European Union (EU) for compassionate use.As announced, Napo has previously provided crofelemer powder for oral solution to treat select infant and pediatric IF...
Read more








